Skye Bioscience Announces Participation at Upcoming Investor Conferences
San Diego, California--(Newsfile Corp. - September 22, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid system to treat diseases with inflammatory, fibrotic, and metabolic processes, with a current focus on the CB1 pathway, announced today that it will be presenting a corporate overview at the 2023 Cantor Global Healthcare Conference and the 16th Annual LD Micro Main Event.
2023 Cantor Global Healthcare Conference
Presenter: Punit Dhillon, Chairman and CEO
Presentation date: Wednesday, September 27, 2023
Presentation time: 11:30 AM ET
Location: Intercontinental Barclay New York Hotel, New York
Mr. Dhillon will be available for 1:1 meetings onsite with registered investors during the conference.
16th Annual LD Micro Main Event
Presenter: Tu Diep, Chief Development Officer
Presentation date: Tuesday, October 3
Presentation time: 4:00 PM PT
Location: Luxe Sunset Boulevard Hotel, California
We invite interested parties to register to watch the presentation virtually here: https://me23.sequireevents.com.
Mr. Diep and Kaitlyn Arsenault, Skye's Chief Financial Officer, will be available for 1:1 meetings onsite throughout the conference.
About Skye Bioscience
Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system, initially through modulation of the CB1 receptor. Backed by leading biotechnology venture investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first- and only-in-class therapeutics with significant clinical and commercial differentiation. Nimacimab, a negative allosteric modulating antibody, inhibits peripheral CB1 with unprecedented safety and tolerability. Skye plans to start a Phase 2 basket study of nimacimab for chronic kidney disease in Q1 2024 and is also evaluating potential development paths for related to obesity/weight loss. SBI-100 Ophthalmic Emulsion is a CB1 agonist that is a potential treatment for glaucoma; it will start Phase 2 in Q4 2023, with an interim data readout in Q1 2024. For more information, please visit: https://www.skyebioscience.com.
CONTACT
Investor Relations
Email: ir@skyebioscience.com
Phone: (858) 410-0266
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, including statements regarding our product development, business strategy, timing of clinical trials and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "anticipated," "plans," "goal," "focus," "aims," "intends," "believes," "can," "could," "challenge," "predictable," "will," "would," "may" or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/181466
SOURCE Skye Bioscience, Inc.
Released September 22, 2023